Novo Nordisk has reported a profit beat, driven by the performance of its weight-loss pill. The company has slightly raised its outlook, suggesting a strong start for its product in the market. The development may be impacting the competitive landscape with Eli Lilly, with some indications that Novo Nordisk is gaining ground, although the extent of this shift is unclear.